Interleukin (IL)-35 is raising our expectations

Purpose: To elucidate and discuss the role of IL-35 in immunity to parasitic and bacterial infections as well as in autoimmunity in terms of its anti-infammatory properties, we highlight significant findings on this novel member of the IL-12 family. Methods: Studies using genetically defcient mice h...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	NING-WEI,ZHAO
Lenguaje:	English
Publicado:	Sociedad Médica de Santiago 2010
Materias:	IL-12 IL-35 Treg cells Teff cells
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872010000600015
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872010000600015
record_format	dspace
spelling	oai:scielo:S0034-988720100006000152010-08-31Interleukin (IL)-35 is raising our expectationsNING-WEI,ZHAO IL-12 IL-35 Treg cells Teff cells Purpose: To elucidate and discuss the role of IL-35 in immunity to parasitic and bacterial infections as well as in autoimmunity in terms of its anti-infammatory properties, we highlight significant findings on this novel member of the IL-12 family. Methods: Studies using genetically defcient mice have greatly enhanced our understanding of the biology of IL-35. On the basis of data derived from the analysis of these genetically deficient mice published by NIH, we focus on the key features of this heterodimeric cytokine, especially its relation to the other IL-12 family members, and discuss its potential relevance to the clinical usage. Principal fndings: IL-35 is required for the CD4+CD25+ Treg cells-mediated immune regulation, the alleviation of some inflammatory responses, as well as the expansion of CD4+CD25- Teff cells simultaneously. Moreover, administration or augmentation of IL-35 suppresses some diseases of autoimmune or allergic origin like collagen-induced arthritis or Helicobacter- induced colitis in animal models, demonstrating its potential in therapy of diseases mediated by inflammatory cytokines. However, some questions involving it are still unclear, including the composition of IL-35 receptor, IL-35-related cell signaling pathway, the different expression patterns of IL-35 between human and murine T cells, etc. Conclusion: As our understanding of the IL-35 is rapidly growing and changing, it will bring us more therapeutic strategies towards some intractable immune diseases such as Lupus Erythematosus.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.138 n.6 20102010-06-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872010000600015en10.4067/S0034-98872010000600015
institution	Scielo Chile
collection	Scielo Chile
language	English
topic	IL-12 IL-35 Treg cells Teff cells
spellingShingle	IL-12 IL-35 Treg cells Teff cells NING-WEI,ZHAO Interleukin (IL)-35 is raising our expectations
description	Purpose: To elucidate and discuss the role of IL-35 in immunity to parasitic and bacterial infections as well as in autoimmunity in terms of its anti-infammatory properties, we highlight significant findings on this novel member of the IL-12 family. Methods: Studies using genetically defcient mice have greatly enhanced our understanding of the biology of IL-35. On the basis of data derived from the analysis of these genetically deficient mice published by NIH, we focus on the key features of this heterodimeric cytokine, especially its relation to the other IL-12 family members, and discuss its potential relevance to the clinical usage. Principal fndings: IL-35 is required for the CD4+CD25+ Treg cells-mediated immune regulation, the alleviation of some inflammatory responses, as well as the expansion of CD4+CD25- Teff cells simultaneously. Moreover, administration or augmentation of IL-35 suppresses some diseases of autoimmune or allergic origin like collagen-induced arthritis or Helicobacter- induced colitis in animal models, demonstrating its potential in therapy of diseases mediated by inflammatory cytokines. However, some questions involving it are still unclear, including the composition of IL-35 receptor, IL-35-related cell signaling pathway, the different expression patterns of IL-35 between human and murine T cells, etc. Conclusion: As our understanding of the IL-35 is rapidly growing and changing, it will bring us more therapeutic strategies towards some intractable immune diseases such as Lupus Erythematosus.
author	NING-WEI,ZHAO
author_facet	NING-WEI,ZHAO
author_sort	NING-WEI,ZHAO
title	Interleukin (IL)-35 is raising our expectations
title_short	Interleukin (IL)-35 is raising our expectations
title_full	Interleukin (IL)-35 is raising our expectations
title_fullStr	Interleukin (IL)-35 is raising our expectations
title_full_unstemmed	Interleukin (IL)-35 is raising our expectations
title_sort	interleukin (il)-35 is raising our expectations
publisher	Sociedad Médica de Santiago
publishDate	2010
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872010000600015
work_keys_str_mv	AT ningweizhao interleukinil35israisingourexpectations
_version_	1718436511341346816

Interleukin (IL)-35 is raising our expectations

Ejemplares similares